New data from the American Academy of Dermatology’s 2026 Annual Meeting is showing a clear pattern of mistakes in psoriasis therapy escalation. These aren’t small slip-ups. We’re talking about things like waiting too long to start a biologic or not adjusting doses when a treatment isn’t working, and it’s leading to worse patient outcomes and higher healthcare costs. These missteps make it obvious that dermatologists need to rethink their strategies. I’m starting to think our current protocols aren’t really equipping clinicians for the long haul of psoriasis management.
Key Takeaways
- Get patients on a biologic within six months of a moderate-to-severe diagnosis. It makes a huge difference for their long-term control and quality of life.
- A common trap is being too hesitant to escalate a dose or switch biologics when a patient isn’t responding, usually because of worries about cost or side effects.
- You have to use objective scores like the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI) regularly. It’s the only way to know when it’s time to make a change.
- Actually talking with your patients about their goals and barriers makes them stick to the treatment plan and improves results.
| Aspect | Suboptimal Therapy Escalation | Optimized Therapy Escalation |
|---|---|---|
| Biologic Initiation Timing | Delayed, waiting until non-biologics are exhausted | Within 6 months of diagnosis for moderate/severe |
| Treatment Adjustment | Delaying changes when response is poor | Quick re-evaluation and adjustment if goals aren’t hit |
| Patient Outcomes | Poor disease control, more suffering, higher risk | Better long-term control, improved quality of life |
| Healthcare Burden | Higher costs, resource strain (8% increase in 3 years) | Fewer complications, potential for lower long-term costs |
| Assessment Tools | Inconsistent or just subjective | Regular PASI and DLQI use for objective data |
| Patient Involvement | Patient input is limited | Open talks, shared decisions to boost adherence |
“US Health Secretary Robert F Kennedy Jr. has released plans to loosen restrictions on controversial peptides. The plans, which were announced in the US Federal Register on Wednesday, say Kennedy would allow compounding pharmacies to prepare six popular peptides, which have not been approved by the Food and Drug Administration (FDA).”
Context and Current Challenges
Psoriasis is a chronic inflammatory skin condition, and managing it requires a flexible plan. Even with a lot of effective therapies like topicals, phototherapy, and systemics, getting to sustained remission is rarely a straight shot. The American Academy of Dermatology (AAD) confirmed this in a 2025 report, showing that nearly 30% of patients with moderate to severe psoriasis either fail on a new systemic therapy or lose efficacy within two years. That figure tells me the problem isn’t just the drugs, but how we’re escalating and modifying them.
A classic mistake is holding off on biologics for too long. Many clinicians, being cautious, want to exhaust every non-biologic option first, even when the patient shows little response and their daily life is seriously affected. This waiting game just means prolonged suffering for the patient, a worse disease burden, and ironically, higher overall costs from managing complications and paying for ineffective treatments. “We see patients who have endured years of inadequate control on methotrexate or cyclosporine when they could have benefited immensely from a biologic much earlier,” said Dr. Elena Petrova, a top dermatologist at the Mayo Clinic, during a panel. And let’s be honest, this hesitation isn’t just clinical. It’s often administrative, driven by insurance hurdles and prior authorization fights that get in the way of timely intervention.
Implications for Patient Care and Healthcare Systems
The consequences of escalating therapy too slowly go way beyond the patient’s discomfort. Delaying effective treatment can lead to psoriatic arthritis getting worse, an increased cardiovascular risk, and significant psychological distress. A study in the Lancet in late 2024 was stark, finding that patients with poorly controlled psoriasis had a 1.5-fold higher incidence of major adverse cardiovascular events compared to those whose disease was well-managed. This shows that a condition we often see as primarily dermatological has serious, systemic effects.
These inefficient treatment pathways also put a strain on healthcare resources. All the extra office visits for treatments that aren’t working, the hospitalizations for severe flares, and the eventual need for more aggressive interventions all add to the bill. An analysis by Reuters in March 2025 indicated that the average annual cost of managing severe psoriasis in the U.S. jumped by 8% over the past three years. This happened in part because of the belated adoption of highly effective (and expensive) biologic therapies after other options fail. The cost problem is the entire cascade of care, not just one medication’s price tag.
What’s Next: Refining Clinical Practice
So how do we fix these common mistakes? It’s not one single thing. First, we need updated guidelines that push for earlier consideration of biologics, specifically for patients with moderate to severe psoriasis who don’t get at least a 75% PASI score reduction within 12 to 16 weeks of starting a conventional systemic. For a lot of practitioners, this is going to mean a shift in thinking away from a rigid step-wise approach toward one that prioritizes getting rapid disease control.
Second, we all need to get better at monitoring treatment response and recognizing the signs of failure. That means consistently using validated tools like the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI) to objectively track progress instead of just going with a gut feeling. If a patient isn’t hitting the agreed-upon treatment goals, you have to re-evaluate the regimen right away, which could mean escalating the dose or switching to a different mechanism of action. Finally, you have to bring the patient into the loop, talking about their expectations, adherence issues, and preferences. When patients are active participants in their care, you get better engagement and better results.
Getting past the inertia in psoriasis therapy escalation requires a proactive, evidence-based strategy. It’s the only way to make sure our patients get the most effective treatment right when they need it.